TNF and inflammatory bowel disease: Aden et al. [24] noted that the levels of SCFAs, particularly butyrate acid and substrates involved in butyrate synthesis, were significantly associated with clinical remission after treatment with TNF inhibitors and may be a clinical marker of therapeutic efficacy in IBD.